Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis

OBJECTIVES: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence of a cancer diagnosis in subjects who participated in the ongoing clinical trial of elcatonin....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Osteoporos Sarcopenia
Главные авторы: Okamoto, Hiroaki, Shibazaki, Nayumi, Yoshimura, Takeshi, Uzawa, Toyonobu, Sugimoto, Toshitsugu
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Society of Osteoporosis 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7093680/
https://ncbi.nlm.nih.gov/pubmed/32226828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2020.02.001
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы